📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. (2020)

First Author: Mullin S

Attributed to: Glucocerebrosidase mutations in Parkinson disease:molecular pathogenesis,and the basis for personalised therapy with small molecule chaperones funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1001/jamaneurol.2019.4611

PubMed Identifier: 31930374

Publication URI: http://europepmc.org/abstract/MED/31930374

Type: Journal Article/Review

Volume: 77

Parent Publication: JAMA neurology

Issue: 4

ISSN: 2168-6149